

# Factsheet

Marketing Material

## Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C

A sub fund of Xtrackers (IE) Plc

This factsheet is as at May 31, 2024 unless otherwise specified

### At a Glance

- Provides diversified exposure to global equities
- Provides exposure to up to 100 stocks which are exposed to themes linked to genomic healthcare innovation
- ESG Screened methodology

### Fund information

ISIN	IE000KD0BZ68
Share class currency	USD
Fund Currency	USD
Fund launch date	12.07.2022
Share class launch date	12.07.2022
Domicile	Ireland
Portfolio Methodology	Direct Replication (physically)
Custodian	State Street Custodial Services (Ireland) Limited
All-in fee <sup>1</sup>	0.30% p.a.
Income treatment	Capitalizing
NAV per Share	USD 29.12
Total Fund Assets	USD 3.46 Million
Total Shares Outstanding	118'888
Reporting Fund	Yes
Transparency according to Regulation (EU) 2019/2088	Article 8. Financial product integrates ESG characteristics (please find further information in the section „Downloads“)

<sup>1</sup> A Glossary can be found on [etf.dws.com](https://etf.dws.com).

### Performance

» [Historical Performance \(online\)](#)

### Listing and trading information

Exchange	Bloomberg Ticker	Reuters RIC	Trading Currency
Borsa Italiana	XGEN IM	XGEN.MI	EUR
London Stock Exchange	XGEN LN	XGEN.L	USD
London Stock Exchange	XGES LN	XGES.L	GBP
SIX - Swiss Exchange	XGEN SW	XGEN.S	CHF
XETRA	XGEN GR	XGEN.DE	EUR

### Key Risks

The Fund is exposed to the currency markets which may be highly volatile. Large price swings can occur in such markets within very short periods and may result in your investment suffering a loss.

The Fund has a focus on a single or narrow range of industry, sector or types of companies and performance may not reflect a rise in broader markets. The value of an investment in shares will depend on a number of factors including, but not limited to, market and economic conditions, sector, geographical region and political events. The Fund is exposed to less economically developed economies (known as emerging markets) which involve greater risks than well developed economies. Political unrest and economic downturn may be more likely and will affect the value of your investment. The Fund invests in small and mid-capitalisation companies, which potentially involves greater risks compared to investing in large capitalisation companies. The shares may have less liquidity and could experience more price swings (or volatility) which could adversely affect the value of your investment. The value of your investment may go down as well as up and past performance does not predict future returns. Investor capital may be at risk up to a total loss.

### Index key facts

Index name	MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index
Index provider	MSCI Inc.
Bloomberg symbol	NU738645
Index base currency	USD
Number of Index constituents	95

Source: Index Provider

### Reference Index key features

The MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 Index aims to reflect the performance of the following market:

- Large, medium, and small-capitalisation companies across developed and emerging markets globally
  - Securities must meet a certain relevance score threshold with the theme of technological innovation in the genomic healthcare sector to be eligible for inclusion
  - Securities issued by entities failing to meet the following ESG standards, amongst others, are excluded: (i) are unrated by MSCI ESG Research; (ii) are assigned an MSCI ESG Rating of CCC; (iii) have any involvement in controversial weapons; (iv) are classified by MSCI in their Business Involvement Screening Research as breaching certain revenue thresholds in controversial activities, including, but not limited to, tobacco, conventional weapons, nuclear weapons, civilian firearms, thermal coal and oil sands extraction; and/or (v) fail to comply with the United Nations Global Compact principles
  - Reviewed semi-annually and rebalanced at least quarterly
- Additional information on the index, selection and weighting methodology is available at <https://www.msci.com/>.

## Top 10 ETF constituents

Issuer	ISIN	Weight
MODERNA INC	US60770K1079	7.81%
ICON PLC	IE0005711209	5.09%
VERTEX PHARMACEUTICALS INC	US92532F1003	4.78%
LONZA GROUP AG	CH0013841017	4.76%
THERMO FISHER SCIENTIFIC INC	US8835561023	4.68%
REGENERON PHARMACEUTICALS INC	US75886F1075	4.65%
DANAHER CORP	US2358511028	4.60%
ROCHE HOLDING PAR AG	CH0012032048	4.17%
GILEAD SCIENCES INC	US3755581036	4.08%
ABBOTT LABORATORIES	US0028241000	4.07%

Source: DWS

## About Xtrackers by DWS

DWS Xtrackers Exchange Traded Funds (ETFs) initially launched in 2007 as a specialist in swap-based index replication. Following a period of rapid growth, the Xtrackers ETF platform subsequently evolved into one of Europe's largest providers of physical replication ETFs. We have continually developed our ETFs to provide investors with a comprehensive set of quality investment tools for efficient portfolio allocation.

Today Xtrackers ETFs are listed on eleven stock exchanges globally and have over EUR 196 billion<sup>1</sup> in assets under management (AUM) making Xtrackers the largest European-headquartered provider of ETFs by AUM<sup>2</sup>.

There are over 190 Xtrackers ETFs available, covering a wide range of asset classes and investment exposures.

Xtrackers central tenet is to provide a broad range of efficient, high quality index trackers for our investors.

<sup>1</sup> Source: DWS, as of May 31, 2024

<sup>2</sup> Source: Deutsche Bank ETF Research

## Further information on Xtrackers

DWS CH AG  
Xtrackers Team  
Prime Tower - Hardstrasse 201  
CH-8021 Zürich

Hotline: +41 (44) 227 3747  
Webseite: [www.etf.dws.com/de-ch/](http://www.etf.dws.com/de-ch/)  
E-Mail: [Xtrackers.Switzerland@dws.com](mailto:Xtrackers.Switzerland@dws.com)

## Additional information

A Glossary of Terms is available at [Xtrackers.com](http://Xtrackers.com).

## Disclaimer

The information included in this document is intended to be advertising of the aforementioned financial services / financial products, according to Art. 68 of the Financial Services Act (FinSA). This document has been prepared without consideration of the investment needs, objectives or financial circumstances of any investor. Before making an investment decision, investors need to consider, with or without the assistance of an investment adviser, whether the investments and strategies described or provided by DWS are appropriate in light of their particular investment needs, objectives and financial circumstances. Information in this document has been obtained or derived from sources believed to be reliable and current. However, accuracy or completeness of the sources cannot be guaranteed. DWS does not give tax or legal advice. Investors should seek advice from their own tax experts and lawyers, when considering investments and strategies suggested by DWS. Investments with DWS are not guaranteed, unless specified. Unless notified to the contrary in a particular case, investment instruments are not insured by the Federal Deposit Insurance Corporation ("FDIC") or any other governmental entity, and are not guaranteed by obligations of DWS or its affiliates.

Investments are subject to various risks, including market fluctuations, regulatory change, counterparty risk, possible delays in repayment and loss of income and principal invested. The value of investments can fall as well as rise and you may not recover the amount originally invested at any point in time. Furthermore, substantial fluctuations of the value of the investment are possible even over short periods of time. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject DWS to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions.

The present information may not be reproduced or circulated without our written authorisation. Xtrackers (IE) plc is an undertaking for collective investment in transferable securities (UCITS) in accordance with the applicable laws and regulations and set up as open-ended investment company with variable capital and segregated liability amongst its respective compartments. Investors must buy and must usually sell shares in Xtrackers UCITS ETFs on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying shares and may receive less than the current net asset value when selling them. Before making any investment decision, investors should refer to the Risk Factors in the Prospectus and Key Information Document.

Tax treatment of the Xtrackers UCITS ETFs depends on the individual circumstances of each investor. Xtrackers (IE) plc is incorporated in Ireland

with registered number 393802 and has its registered office at 78 Sir John Rogerson's Quay, Dublin 2, Ireland. DWS Investment S.A. acts as the management company of Xtrackers (IE) plc. The Investment Company may decide to terminate the arrangements made for the marketing of this fund.

The foreign collective investment scheme ("CIS") mentioned above has been authorised by the Swiss Financial Market Supervisory Authority (FINMA) for offering to non-qualified investors in Switzerland, pursuant to the Swiss Federal Act on Collective Investment Schemes of June 23, 2006 ("CISA") The Swiss Representative for this CIS is DWS CH AG, Hardstrasse 201, CH-8005 Zurich. The Swiss Paying Agent is Deutsche Bank (Suisse) SA, Place des Bergues 3, CH-1201 Geneva.

Any investment decision in relation to a fund should be based solely on the latest version of the prospectus, the audited annual and, if more recent, un-audited semi-annual reports and the Key Information Document (KID or Basisinformationsblatt ("BIB")), all of which are available in English upon request to DWS Investment S.A., 2, Boulevard Konrad Adenauer, L-1115 Luxembourg or on [www.Xtrackers.com](http://www.Xtrackers.com). Investors can also request these documents from the registered office of the Swiss Representative at DWS CH AG, Hardstrasse 201, CH-8005 Zurich or on <https://etf.dws.com/en-ch/> in English and <https://etf.dws.com/de-ch/> in German. In respect of the units offered in Switzerland, the place of performance is the registered office of the Representative. The place of jurisdiction shall be at the registered office of the Representative or at the registered office or domicile of the investor. A summary of investor rights is available at [www.etf.dws.com](http://www.etf.dws.com) under "About Us – How to Complain?".

**Past performance is no guarantee of future results; nothing contained herein shall constitute any representation or warranty as to future performance.**

© DWS CH AG 2024. Authorised and regulated by the Swiss Financial Market Supervisory Authority.

## Index Disclaimer

The MSCI Genomic Healthcare Innovation UCITS ETF ARE NOT SPONSORED, ENDORSED, SOLD OR PROMOTED BY MSCI INC. ("MSCI") OR ANY OF ITS AFFILIATES, INFORMATION PROVIDERS OR OTHER THIRD PARTY INVOLVED IN, OR RELATED TO, COMPILING, COMPUTING OR CREATING ANY MSCI INDEX (COLLECTIVELY, THE "MSCI PARTIES"). THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES ARE SERVICE MARK(S) OF MSCI OR ITS AFFILIATES AND HAVE BEEN LICENSED FOR USE FOR CERTAIN PURPOSES BY PRINCIPAL. NONE OF THE MSCI PARTIES MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, TO THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY REGARDING THE ADVISABILITY OF INVESTING IN

FUNDS GENERALLY OR IN THESE FUNDS PARTICULARLY OR THE ABILITY OF ANY MSCI INDEX TO TRACK CORRESPONDING STOCK MARKET PERFORMANCE. MSCI OR ITS AFFILIATES ARE THE LICENSORS OF CERTAIN TRADEMARKS, SERVICE MARKS AND TRADE NAMES AND OF THE MSCI INDEXES WHICH ARE DETERMINED, COMPOSED AND CALCULATED BY MSCI WITHOUT REGARD TO THESE FUNDS OR THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY. NONE OF THE MSCI PARTIES HAS ANY OBLIGATION TO TAKE THE NEEDS OF THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY INTO CONSIDERATION IN DETERMINING, COMPOSING OR CALCULATING THE MSCI INDEXES. NONE OF THE MSCI PARTIES IS RESPONSIBLE FOR OR HAS PARTICIPATED IN THE DETERMINATION OF THE TIMING OF, PRICES AT, OR QUANTITIES OF THESE FUNDS TO BE ISSUED OR IN THE DETERMINATION OR CALCULATION OF THE EQUATION BY OR THE CONSIDERATION INTO WHICH THESE FUNDS ARE REDEEMABLE. FURTHER, NONE OF THE MSCI PARTIES HAS ANY OBLIGATION OR LIABILITY TO THE ISSUER OR OWNERS OF THESE FUNDS OR ANY OTHER PERSON OR ENTITY IN CONNECTION WITH THE ADMINISTRATION, MARKETING OR OFFERING OF MSCI Genomic Healthcare Innovation UCITS ETF.

ALTHOUGH MSCI SHALL OBTAIN INFORMATION FOR INCLUSION IN OR FOR USE IN THE CALCULATION OF THE MSCI INDEXES FROM SOURCES THAT MSCI CONSIDERS RELIABLE, NONE OF THE MSCI PARTIES WARRANTS OR GUARANTEES THE ORIGINALITY, ACCURACY AND/OR THE COMPLETENESS OF ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. NONE OF THE MSCI PARTIES MAKES ANY WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY THE ISSUER OF THE FUNDS, OWNERS OF THE FUNDS, OR ANY OTHER PERSON OR ENTITY, FROM THE USE OF ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. NONE OF THE MSCI PARTIES SHALL HAVE ANY LIABILITY FOR ANY ERRORS, OMISSIONS OR INTERRUPTIONS OF OR IN CONNECTION WITH ANY MSCI INDEX OR ANY DATA INCLUDED THEREIN. FURTHER, NONE OF THE MSCI PARTIES MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF ANY KIND, AND THE MSCI PARTIES HEREBY EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO EACH MSCI INDEX AND ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL ANY OF THE MSCI PARTIES HAVE ANY LIABILITY FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR ANY OTHER DAMAGES (INCLUDING LOST PROFITS) EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

No purchaser, seller or holder of this security, product or Funds, or any other person or entity, should use or refer to any MSCI trade name, trademark or service mark to sponsor, endorse, market or promote this security without first contacting MSCI to determine whether MSCI's permission is required. Under no circumstances may any person or entity claim any affiliation with MSCI without the prior written permission of MSCI.

